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Abstract: Alterations in the Checkpoint kinase (CHEK1) gene, its regulation, and the possible clinical
outcomes in human solid tumors have not been previously examined. Therefore, the present study
was carried out to evaluate the expression of CHEK1 in solid tumors as well as the mechanism by
which it can be regulated through non-coding RNAs. The expression of CHEK1 was investigated using
Oncomine analysis. cBioPortal, Kaplan–Meier Plotter, and PrognoScan were performed to identify
the prognostic roles of this gene in solid tumors. The copy number alteration, mutation, interactive
analysis, and visualization of the altered networks were performed by cBioPortal. The molecular
binding analysis was carried out by Schrodinger suite, PATCHDOCK, and discovery studio visualizer.
The study demonstrated that the CHEK1 gene was differentially expressed in four different cancers,
and that reduced CHEK1 mRNA expression is an unfavorable prognostic factor for patients with
gastric and colorectal cancer. The molecular docking results showed that the CHEK1 gene can be
regulated by microRNAs (miR-195-5p) due to the number of stable hydrogen atoms observed within
the distance of 2.0 Å and the favorable amino acids (Ala221, Ile353, Ile365, Ile756, Val797, Val70,
Val154, Ile159, Val347, Tyr804, Phe811, Tyr815, and Phe156) identified in the binding pocket of the
argonaute protein. Due to the possibility of CHEK1’s involvement in solid tumors, it may potentially
be a target for therapeutic intervention in cancer. Further studies into the interaction between CHEK1
and other co-expressed genes may give further insight into other modes of regulation of this gene in
cancer patients.
Keywords: solid tumor; CHEK1; gene expression; molecular docking; cancer; argonaute protein
1. Introduction
Carcinogenesis is the development of a malignant tumor in healthy tissues resulting from
a complex series of events beginning with a single cell that has acquired malignant properties
through genetic or epigenetics alterations. Cancers result from a progressive accumulation of genetic
alterations (mutations) in many different genes. These mutations include alteration of the copy number,
translocation events, base insertion, duplication, deletions, and substitutions [1–3]. All cancers,
including solid tumors, display recurrent chromosomal abnormalities. However, the exact biological
significance relating to gene expression alterations in important genes remains unclear in solid tumors.
Advances in the understanding of genetic alterations associated with solid tumors are retarded because
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of difficulties in the induction of neoplastic cells of many tumors to divide in vitro. Cancer treatments
employ DNA-damaging therapies to inhibit tumor cell proliferation and induce cell cycle arrest [4].
Since many solid tumors significantly rely on checkpoint kinase 1 (CHEK1)-mediated cell cycle arrest,
especially in the absence of the tumor protein-53 (TP53) gene [5], the CHEK1 gene can be considered as
a potential target during the development of novel cancer therapies.
CHEK1, a member of the CHEK family, is a serine/threonine-specific protein kinase known to
mediate cell cycle arrest in response to DNA damage [6]. The mechanism of action of this gene
involves the activation of ataxia telangiectasia mutated (ATM)/ ataxia telangiectasia and Rad3-related
protein (ATR), which triggers the phosphorylation of TP53 and CHEKs. This, in turn, inhibits CDC25
phosphatases, thereby preventing the activation of CDK1/Cyclin B and consequently leading to G2/M
arrest and initiation of DNA repair [4,7,8]. It was reported that CHEK1 is altered in 0.80% of all cancers
and mutated in 2.62% of malignant solid tumors [9].
More so, the expression of this gene has been implicated in several diseases. In neurodegenerative
diseases, CHEK1 abnormalities were associated with dementia and loss of protection in Alzheimer’s
disease [10].
CHEK1 is majorly involved in the coordination of DNA repair and therefore is an area of great
interest in cancer development and treatment [11]. The CHEK1 gene was previously thought to
function as a tumor suppressor because of the regulatory role it plays in DNA damage. However,
no evidence of homozygous loss of function mutants for CHEK1 in human cancers was reported [12].
Rather, this gene has been revealed to be overexpressed in several solid tumors. The correlation of
CHEK1 expression with tumor grade and disease recurrence was also reported, suggesting its role in
tumor development [11,13]. Studies have shown that complete loss of CHEK1 suppresses chemically
induced carcinogenesis, and its low expression may result in tumor progression [13].
Although different studies have reported CHEK1 mutations in endometrial, colorectal, and stomach
carcinomas with microsatellite instability [14–16], the potential role of the CHEK1 gene in the
pathogenesis of human cancer is not well defined. CHEK1 has been revealed to be overexpressed in
various tumors compared to the adjacent normal tissues [17–20]. Tumor cells with increased levels of
CHEK1 acquire survival advantages due to the ability to resist a higher level of DNA damage. Increased
levels of CHEK1 may contribute to chemotherapy resistance [21]. CHEK1 was also regulated at the
post-transcriptional level by microRNAs [22,23] which are key regulators of tumor growth and response
to cancer treatment [24–26]. It is worthwhile to understand the mechanism of microRNA–CHEK1
regulation in solid tumors to provide potential new targets and mechanisms as therapeutic options.
Since the pattern of genetic alterations in human solid tumors is distinct and tends to display
multiple clonal structural and numeric chromosome rearrangements, the identification of differentially
expressed genes between normal cells and its disease state will be a lead in the identification of genes
associated with solid tumors.
Methods, including nucleic acid substitution, serial analysis of gene expression, and differential
display, have previously been used to identify cancer-related genes. Lately, the expression of microarray
analysis techniques, which allows quantitative and large-scale analysis of gene expression, has been
used. Additionally, several web-based databases are being developed to describe new chromosomal
abnormalities in the context of tumor histopathology. Therefore, the aim of this study was to evaluate
the expression signature, prognostic value, and possible functions of the CHEK1 gene in solid tumors
using in silico and molecular docking approaches. Solving cancer problems with genomic data and
various in silico approaches is a cost-effective approach in cancer research.
2. Results
2.1. mRNA Expression Levels of CHEK1 in Cancers (Oncomine)
The transcription levels of CHEK1 were investigated to explore its role in cancer. Relative to
normal tissues, the mRNA expression levels of this gene in cancers, especially solid tumors, using
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the Oncomine database were significantly overexpressed. As shown in Figure 1, it can also be
underexpressed, making this gene function as either oncogenic or against oncogenic activities based on
the cancer types. Therefore, detailed analyses of CHEK1 were further considered for further analysis.
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Figure 1. The expression levels of CHEK1 in different types of solid tumors (Oncomine database and 
cBioPortal). (A) This plot indicates the numbers of datasets with statistically significant (p < 0.01) 
mRNA over-expression (red) or down-expression (blue) of CHEK1 (different types of cancer vs. 
corresponding normal tissue). The threshold was designed with the following parameters: p-value of 
1.0 × 10−8, 2× fold change, and gene ranking of 1%. (B) Analysis of CHEK1 mRNA levels in 30 types of 
human cancers. The median and interquartile ranges are shown in each box. 
2.2. Expression Levels of CHEK1 in Selected Solid Tumors 
The Oncomine database was used to investigate the transcript expression of CHEK1 in cancers. 
CHEK1 was used as the query and the result showed that the gene was overexpressed in brain, 
cervical, colorectal, and gastric cancers and also underexpressed in another brain cancer when 
compared to the normal counterpart (Table 1, Figure 2). 
Table 1. Expression of CHEK1 in solid tumors (rank of 1%). 
Cancer Subtype p-Value Fold 
Change 
Sample Ref. 
Brain Glioblastoma 1.36 × 10−26 4.157 180 [27] 
 Glioblastoma 4.67 × 10−12 −4.170 101 [28] 
Cervical Cervical Squamous Cell Carcinoma 7.71 × 10−12 2.319 45 [29] 
Colorectal Colon Adenoma 2.23 × 10−12 2.948 64 [30] 
Gastric Gastric cancer 2.23 × 10−9 2.409 180 [31] 
Figure 1. The expression levels of CHEK1 in different types of solid tumors (Oncomine database and
cBioPortal). (A) This plot indicates the numbers of datasets with statistically significant (p < 0.01) mRNA
over-expression (red) or down-expression (blue) of CHEK1 (different types of cancer vs. corresponding
normal tissue). The threshold was designed with the following parameters: p-value of 1.0 × 10−8,
2× fold change, and gene ranking of 1%. (B) Analysis of CHEK1 mRNA levels in 30 types of human
cancers. The median and interquartile ranges are shown in each box.
2.2. Expression Levels of CHEK1 in Selected Solid Tumors
The Oncomine database was used to investigate the transcript expression of CHEK1 in cancers.
CHEK1 was used as the query and the result showed that the gene was overexpressed in brain, cervical,
colorectal, and gastric cancers and also underexpressed in another brain cancer when compared to the
normal counterpart (Table 1, Figure 2).
Table 1. Expression of CHEK1 in solid tumors (rank of 1%).
Cancer Subtype p-Value Fold Change Sample Ref.
Brain Glioblastoma 1.36 × 10−26 4.157 180 [27]
Glioblastoma 4.67 × 10−12 −4.170 101 [28]
Cervical Cervical Squamous Cell Carcinoma 7.71 × 10−12 2.319 45 [29]
Colorectal Colon Adeno 2.23 × 10−12 2.948 64 [30]
Gastric Gastric cancer 2.23 × 10−9 2.409 180 [31]
Gastric Intestinal Type Adenocarcinoma 2.99 × 10−12 3.936 69 [32]
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Figure 2. CHEK1 analysis in different cancer types. The box plot comparing specific CHEK1 
expression in normal (left plot) and cancer tissue (right plot) was derived from the Oncomine 
database. The fold change of CHEK1 in various types of cancers was expressed as the forest plot (A). 
The analysis was shown in two sample types, glioblastoma carcinoma relative to normal brain (B), in 
cervical carcinoma relative to normal cervical tissue (C), in gastric carcinoma relative to normal gastric 
tissue (D), and in colorectal carcinoma relative to normal colorectum (E). 
2.3. Survival Analysis 
Estimation of the prognostic value and overall survival of patients with CHEK1 expression was 
performed in selected solid tumors. Kaplan–Meier1 Plotter and PrognoScan web-based tools were 
used to study the expression of the CHECK1 gene with respect to its clinical prognosis. The result 
shows that downregulation of CHEK1 expression in patients with gastric adenocarcinoma is 
associated with poor prognosis. Contrastingly, the result obtained in lung adenocarcinoma, ovarian 
cancer, and breast cancer suggested that high expression of CHEK1 is associated with poor survival 
rates (Figure 3). 
  
Figure 2. analysis in different cancer types. The box plot comparing s ecific CHEK1 expression
in normal (left plot) and cancer tissue (right plot) was derived from the Oncomine database. The fold
change of CHEK1 in vari us types of cancers was expressed as the forest plot (A). The analysis was
shown in two sample types, glioblastoma carcinoma relative to nor al brain (B), in cervical carcinoma
relative to nor al cervical tissue (C), in gastric carcinoma relative to normal gastric tissue (D), and in
colorectal carcinoma relative to normal colorectum (E).
2.3. Survival Analysis
Estimation of the prognostic value and overall survival of patients with CHEK1 expression was
performed in selected solid tumors. Kaplan–Meier1 Plotter and PrognoScan web-based tools were used
to study the expression of the CHECK1 gene with respect to its clinical prognosis. The result shows
that downregulation of CHEK1 expression in patients with gastric adenocarcinoma is associated with
poor prognosis. Contrastingly, the result obtained in lung adenocarcinoma, ovarian cancer, and breast
cancer suggested that high expression of CHEK1 is associated with poor survival rates (Figure 3).
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Figure 3. Overall survival analysis of CHEK1. The survival curve comparing the patient with high and
low expression in four selected solid tumors was plotted from the Kaplan–Meier plotter database.
The prognostic value f ression was reported by the PrognoScan database (Figure 4,
Table 2). The poor prognosis in ovarian cancer patients with higher CHEK1 expression (Figure 5) was
in line with the data from the Kaplan–Meier plotter analysis (Figure 3). This study therefore employed
in silico approaches to demonstrate the oncogenic role of CHEK1 in selected solid tumors
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Figure 4. Meta-analysis of CHEK1 genes in different solid tumors. The statistically significant hazard
ratio in various types of solid tumors was identified from the PrognoScan database in Table 2 and
expressed as the forest plot. The analysis of the survival curve was identified as the threshol of a cox
p-value < 0.05.
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Table 2. The relationship between CHEK1 expression and survival in solid tumor clinical samples.
Cancer Dataset Endpoint PROBE ID N Cox p-Value HR
Bladder GSE13507 Overall Survival ILMN_1664630 165 0.040924 1.35
GSE13507 Disease Specific Survival ILMN_1664630 165 0.00706943 1.75
Brain GSE4271-GPL96 Overall Survi al 205394_at 77 0.000296208 1.92
Breast GSE12276 Relapse Free Survival 205393_s_at 204 0.000166722 1.46
GSE9195 Distant Metastasis Free Survival 205393_s_at 77 0.00319767 3.57
GSE1456-GPL96 Relapse Free Survival 205394_at 159 0.00259906 2.11
GSE1456-GPL96 Overall Survival 205393_s_at 159 0.0298328 1.78
GSE1456-GPL96 Disease Specific Survival 205394_at 159 0.00442993 2.23
GSE1456-GPL96 Overall Survival 205394_at 159 0.00383569 2.02
GSE1456-GPL96 Relapse Free Survival 205393_s_at 159 0.000924772 2.44
GSE1456-GPL96 Disease Specific Survival 205393_s_at 159 0.00145812 2.60
GSE4922-GPL97 Disease Free Survival 238075_at 249 0.0101338 1.77
Colorectal GSE14333 Disease Free Survival 205394_at 226 0.0121161 0.56
Lung GSE13213 Overall Survival A_23_P116123 117 0.00199884 1.40
GSE31210 Overall Survival 238075_at 204 0.001305 2.39
GSE31210 Relapse Free Survival 205393_s_at 204 0.000142 1.91
GSE31210 Overall Survival 205394_at 204 0.000872076 1.93
Ovarian DUKE-OC Overall Survival 205394_at 133 0.0130251 0.71
GSE8841 Overall Survival 2515 81 0.017998 1.91
2.4. Protein Components of CHEK1
Checkpoint kinases are involved in the regulation of DNA replication and cell cycle progression,
chromatin restructuring, and apoptosis. Despite these common roles, their biological requirements
are different [33]. CHEK1 is mainly involved in mammalian development and viability [34]. Studies
revealed that cancer-associated defects of CHEK1 are extremely rare, and so far seem limited to
carcinomas of the colon, stomach, and endometrium [14–16]. Cytoscape stringAPP plugin was used
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to determine the protein–protein interaction of CHEK1 and its protein partner. This prediction
was based on the curated database, experiment, text-mining, and co-expression/co-occurrence.
The 10 predicted proteins of CHEK1 (with the corresponding gene names) including the predicted
genes are ATM, cell division cycle 25A and C (CDC25A and C), exonuclease 1 (EXO1), claspin
(CLSPN), RAD51recombinase (RAD51), ATR, topoisomerase (DNA) II binding protein 1 (TOPBP1),
minichromosome maintenance complex component 4 (MCM4), and cell division cycle 45 (CDC45).
These genes were further considered for downstream analysis of CHEK1 (Figure 6).
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Figure 6. Identification of known and predicted structural proteins essential for CHEK1. The figure
consists of 11 nodes and 55 edges, with an average node degree of 6.36 and average local clustering
coefficient of 0.855 at a protein-protein (PPI) enrichment p-value of 6.94 × 10−09. With PPI analysis using
STRINGAPP software plugin Cytoscape, all the genes were identified and are relatively important.
2.5. Genetic Alterations of CHEK1
The genetic alterations of CHEK1 were analyzed in all the different cancers available in the
cBioPortal database and the results were compared with those of other genes of interest in Figure 6.
The database was queried for CHEK1 gene mutations in 82,899 samples from 275 studies that covered
the entire set of available cancers (Figure 7).
Additionally, all 10 genes were used as a query to investigate the mutations and copy number
alterations (CNAs) in 12 solid tumor studies. The results are presented in Table 3 and Figure 8.
The highest frequency of alteration is implicated in prostate cancer.
Table 3. Genetic alteration summary of genes of interest in 12 solid tumors.
Cancer CHEK1 ATM CDC25A CDC25C EXO1 CLSPN RAD51 ATR TOPBP1 MCM4
Bladder 2% 14% 2.2% 1% 2% 4% 2.5% 9% 4% 7%
Colon 4% 13% 7% 4% 7% 10% 5% 6% 6% 1%
Breast 0.4% 2.9% 0.2% 0.4% 5% 0.6% 0.8% 1.2% 1.5% 5%
Brain 2.6% 1.4% 1.6% 0.2% 0.6% 0,4% 0.2% 0.8% 0.4% 0.4%
Breast 0.4% 0.5% 0.2% 0.6% 23% 0.7% 0.7% 5% 0.9% 12%
Cervical 4% 6% 1.4% 0.4% 2.2% 3% 1.4% 10% 9% 1.4%
Stomach 2.3% 12% 2.5% 2.1% 6% 3% 0.7% 8% 4% 6%
Liver 1.4% 5% 0.3% 1.4% 8% 0.6% 0.8% 4% 1.1% 7%
Lung 3% 10% 0.8% 2.2% 7% 2.4% 2.6% 4% 2.6% 6%
Ovarian 7% 11% 7% 4% 9% 12% 5% 21% 22% 8%
Prostate 16% 19% 22% 21% 28% 10% 9% 28% 27% 38%
Pancreas 9% 10% 4% 6% 11% 7% 6% 11% 8% 12%
The genetic alterations of all the genes of interest were further queried in the prostate cancer sample as shown in
Figure 8. The Oncoprint feature of the cBioPortal was to determine the copy number alteration frequency of each
individual gene within selected cancer subtypes.
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type of mutations for each gene. Complete samples (114 patients/samples). Queried genes are altered
in 51 (45%) of the queried patients/samples.
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2.6. Co-Expression Profile of CHEK1 in Colorectal Cancer
Additionally, the co-expression profiles for CHEK1 with 20 genes across 36 colorectal carcinomas,
45 colorectal adenocarcinomas, and 24 normal colorectum tissues were investigated (Figure 9).
Interestingly, CHEK1 was co-expressed with minichromosome maintenance complex component
(MCM family) and flap eendonuclease 1 (FEN1) expressed in colorectal cancer. The MCM family
(MCMs) has been reported to be associated with numerous cancer types [35–37], such as the promotion
of metastasis of liver cancer through the Mitogen-activated protein kinase kinase(MEK)/ extracellular
signal-regulated kinases (ERK) pathway (MCM6) [38], as a prognostic factor in patients with lung
squamous cell carcinoma [39]. Many studies indicate the central roles of MCMs in genome stability,
including the regulation of transcription, chromatin remodeling, and checkpoint responses [40–42].
Overexpression of MCMs is clinically correlated with cervical carcinogenesis [43]. On the other
hand, FEN1 is a multifunctional structure-specific nuclease that has a critical role in maintaining
human genome stability. Overexpression of this gene correlates with enhanced proliferation and poor
prognosis of lung cancer [44]. The exact underlying mechanism through which CHEK1 modulates
cancer progression needs to be further investigated.
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2.7. Structural Preparation of miR-195-5p-CHEK1 and Human Argonaute Protein Preparation
The structural model of iR-195-5p and i -195-5p-CHEK1 (miRNA-mRNA) duplex (ligands)
was built from the miRTarBase, RNAfold, and RNA COMPOSER databases r i l ( i r C).
The 3D structu e of human argonaute protein (receptor) was retrieved from the protein data bank (PDB)
and prepare using the Schroding r suite (Fi u e 10D). PROCHECK through the Ramachandra plot
was used to validate the quality before binding (Figur 10E). Furthermore, the molecular docking of
micr RNA–argonaute and microRNA–mRNA-bound argonaute was carried out using PATCHDOCK
at an RMSD of 1.0 to investigate the mechanism of CHEK1 regulation in solid tumors. The result
generated was analyzed in MAESTRO, a Schrodinger software, and visualized using the discovery
studio visualizer (DSV).
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Figure 10. Structural model for molecular docking. (A) Secondary structure of MiR-195-5p, 3D 
structures of (B) MiR-195-5p, and (C) MiR-195-5p-CHEK1. (D) Prepared human argonaute protein 
(Ago) and (E) Ramachandran plot (PDBSum, PROCHECK). The quality of the prepared Ago was 
estimated by the PDBSum server. The residues in most favored regions (A, B, L), the residues in 
Figure 10. Structural model for molecular docking. (A) Secondary structure of MiR-195-5p, 3D structures
of (B) MiR-195-5p, and (C) MiR-195-5p-CHEK1. (D) Prepared human argonaute protein (Ago) and (E)
Ramachandran plot (PDBSum, PROCHECK). The quality of the prepared Ago was estimated by the
PDBSum server. The residues in most favored regions (A, B, L), the residues in additional allowed
regions (a, b, l, p), and residues in generously allowed regions (~a, ~b ~l, ~p). The structural details of
Ago (ID: 4F3T: A) consist of 7 sheets, 9 gamma turns, 13 beta hairpins, 7 beta bulges, 37 strands, and 68
beta turns.
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2.8. Molecular Docking Analysis
A web-based docking tool (PATCHDOCK) was used to study the mode of action of CHEK1
regulation by microRNAs in solid tumors. The PATCHDOCK method is based on the shape
complementarity theory [45]. Criteria, such as strong hydrophobic amino acids together with aromatic
amino acids, are important to binding interactions in terms of the stability between protein receptors
and their ligands. The outputs were ranked according to their geometric shape complementarity score
(Table 4). The strong interactions observed were based on the microRNA minimum folding energy of
-14kcal/mol (miRTarBase), scores, and the specific amino acid residues involved in binding. As evident,
the presence of strong hydrophobic and aromatic amino acid side chains (3.5 Å) (Figure 11; Table 5)
and H-bonds (2.0 Å) is proof that CHEK1 regulation through the human argonaute protein could be
driven by miR-195-5p (Table 6).




Figure 11. The amino acid residues of human argonaute protein participating in the binding analysis 
with each mRNA and microRNAs within a distance of 3.5 Å. (A) Amino acids participating in miR-
195-5-AGO complex, (B) amino acids participating in miR-195-5p-CHEK1 duplex and AGO. 
2.9. Hydrogen Bond Interaction 
Hydrogen bonds (H-bond) play some roles in protein–ligand stability. These roles include 
orientation of the ligand in the receptor cavity (the pose), ligand recognition by protein, and binding 
affinity. As one of the contributors to the docking score, the hydrogen bond interactions in the 
binding pocket of the human argonaute protein when complexed with both microRNA and 
microRNA-mRNA duplex were evaluated. 
This bond predicts the specificity of small molecule binding and its important contribution is 
explicitly incorporated into the molecular interaction to strengthen the binding of ligands to their 
receptors in an energetically favorable manner. The (H bond) interactions were detected between the 
amino acid residues of AGO and atoms of miR-195-5p and miR-195-5p-CHEK1 (Figure 12A and B). 
with a distance of 2.5 Å. Table 6 shows the residues of the amino acids involved in the H-bond 
between the AGO binding pocket and miR-195-5p and miRNA-mRNA within the distance of 2.0 Å. 
The results showed that H-bonds increase with atomic interactions. This result may, therefore, 
support the mode of action of miR-195-5p regulation in the expression of CHEK1 through the RNA-
induced silencing complex. 
  
Figure 11. The amino acid residues of human arg te protein participating in the binding analysis
with each mRNA and microRNAs within a distance of 3.5 Å. (A) Amino acids participating in
miR-195-5-AGO complex, (B) amino acids participating in miR-195-5p-CHEK1 duplex and AGO.
Table 4. Docking scores (PatchDock).
Ago Complex Score Area ACE
miRNA-AGO 20558 3146.10 −386.43
miRNA-mRNA-AGO 21006 3504.30 −275.84
AGO, argonaute; ACE, atomic contact energy.
Table 5. Amino acid residues of the binding pocket of the receptor protein involved in the molecular
interaction with miR-195-5p and miR-195-5p-CHEK1 duplex (2.0 Å).
AGO Complex Hydrophobic AA Aromatic AA
miR-195-5p (41) Ala221, Ile353, Ile365, Ile756, Val797 Ty 804, Phe811, Tyr815
miR-195-5p-CHEK1 (43) Val70, Val154, Ile159, Val347 Phe156
AA; Amino acid.
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Table 6. Hydrogen bond interaction observed in the binding pocket of the human argonaute protein
and miR-195-5p, andmiR-195-5p-CHEK1 within the distance of 2.0 Å.





























































AA; Amino acid, NA; Nucleic acid.
2.9. Hydrogen Bond Interaction
Hydrogen bonds (H-bond) play some roles in protein–ligand stability. These roles include
orientation of the ligand in the receptor cavity (the pose), ligand recognition by protein, and binding
affinity. As one of the contributors to the docking score, the hydrogen bond interactions in the binding
pocket of the human argonaute protein when complexed with both microRNA and microRNA-mRNA
duplex were evaluated.
This bond predicts the specificity of small molecule binding and its important contribution is
explicitly incorporated into the molecular interaction to strengthen the binding of ligands to their
receptors in an energetically favorable manner. The (H bond) interactions were detected between
the amino acid residues of AGO and atoms of miR-195-5p and miR-195-5p-CHEK1 (Figure 12A and
B). with a distance of 2.5 Å. Table 6 shows the residues of the amino acids involved in the H-bond
between the AGO binding pocket and miR-195-5p and miRNA-mRNA within the distance of 2.0 Å.
The results showed that H-bonds increase with atomic interactions. This result may, therefore, support
the mode of action of miR-195-5p regulation in the expression of CHEK1 through the RNA-induced





Figure 12. Hydrogen bond interaction between (A) the residual amino acids of human argonaute 
protein and miR-195-5p, and (B) the residual amino acids of human argonaute protein and miR-195-
5p-CHEK1 duplex (3.5 Å distance).  
3. Discussion 
CHEKs belong to the mammalian Ser/Thr kinase protein family, which has two members: 
CHEK1 and CHEK2. CHEK1 activation must be timely regulated to ensure its proper functioning. 
The essential mechanism controlling CHEK1 regulation is the phosphorylation of Ser317 and Ser345 
at the C-terminal domain, which leads to catalytic activation [46] catalyzed by ATR and ATM kinases 
[47–49]. This study extensively investigated the role of CHEK1 in solid tumors as well as the 
mechanism by which it can be regulated through molecular docking with human argonaute protein 
assisted by a known microRNA found to be crucial in cancer (miR-195-5p). 
To understand the role of checkpoints in solid tumors, the transcription levels of CHEK1 in 
normal and cancer tissues were evaluated in the Oncomine database. The various underlying 
threshold parameters were set as follows: p-value of 1.0 × 10−8, 2× fold change, and gene ranking of 
1%. CHEK1 was found to be overexpressed in some cancer tissues when compared to normal tissues. 
The cancer genome atlas contains a large collection of RNA sequencing data and is a useful tool 
to explore the molecular basis of cancer [50]. By accessing TCGA data via cBioPortal, the mRNA levels 
of CHEK1 in various solid tumors were found to be differentially expressed in many cancer types 
(Figure 1b). These were the basis for further downstream analyses of CHEK1. 
CHEK1 gene expression was compared from a total of 440 different analyses, and the data was 
collected from various studies deposited in the Oncomine database. Based on the defined parameters, 
CHEK1 expression was statistically significant in six studies, and it was reported to be upregulated 
in brain, central nervous system (CNS), cervical, CRC, and gastric cancers in five studies; in contrast, 
one of the studies reported reduced expression of CHEK1 in brain and CNS cancers. The majority of 
previous studies reported that CHEK1 expression is upregulated in various cancers [19,47,51,52], 
which is in agreement with this study. Various mechanisms involved in the regulation of CHEK1 
expression and activation were previously described [53–55]. It can also be regulated at the post-
transcriptional level by microRNAs [23,56], which are key regulators of tumor growth and response 
to treatment [57]. The expression of CHEK1 was further validated, and demonstrated that the CHEK1 
gene may possess either oncogenic or anti-oncogenic characteristics, depending on the type of cancer. 
StringAPP plugin Cytoscape prediction indicated that CHEK1 interacts with 10 other proteins, 
namely: Ataxia telangiectasia mutated (ATM), cell division cycle 25A and C (CDC25A and C), 
exonuclease 1 (EXO1), claspin (CLSPN), RAD51 recombinase (RAD51), ataxia telangiectasia and 
Rad3-related protein (ATR), topoisomerase II binding protein 1 (TOPBP1), minichromosome 
maintenance complex component 4 (MCM4), and cell division cycle 45 (CDC45). These genes (Figure 
6) were predicted based on co-expression/occurrence, experimental, text-mining, or curated 
databases. Further research is recommended to give insight into the relationship of each gene with 
respect to CHEK1 in solid tumors. 
i r 12. Hydrogen bond interaction between (A) the residual amino acids of human argonaute protein
and miR-195-5p, and (B) the residual amino cids of human argonaute protein and miR-195-5p-CHEK1
duplex (3.5 Å distance).
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3. Discussion
CHEKs belong to the mammalian Ser/Thr kinase protein family, which has two members: CHEK1
and CHEK2. CHEK1 activation must be timely regulated to ensure its proper functioning. The essential
mechanism controlling CHEK1 regulation is the phosphorylation of Ser317 and Ser345 at the C-terminal
domain, which leads to catalytic activation [46] catalyzed by ATR and ATM kinases [47–49]. This study
extensively investigated the role of CHEK1 in solid tumors as well as the mechanism by which it can be
regulated through molecular docking with human argonaute protein assisted by a known microRNA
found to be crucial in cancer (miR-195-5p).
To understand the role of checkpoints in solid tumors, the transcription levels of CHEK1 in normal
and cancer tissues were evaluated in the Oncomine database. The various underlying threshold
parameters were set as follows: p-value of 1.0 × 10−8, 2× fold change, and gene ranking of 1%. CHEK1
was found to be overexpressed in some cancer tissues when compared to normal tissues.
The cancer genome atlas contains a large collection of RNA sequencing data and is a useful tool to
explore the molecular basis of cancer [50]. By accessing TCGA data via cBioPortal, the mRNA levels
of CHEK1 in various solid tumors were found to be differentially expressed in many cancer types
(Figure 1b). These were the basis for further downstream analyses of CHEK1.
CHEK1 gene expression was compared from a total of 440 different analyses, and the data was
collected from various studies deposited in the Oncomine database. Based on the defined parameters,
CHEK1 expression was statistically significant in six studies, and it was reported to be upregulated in
brain, central nervous system (CNS), cervical, CRC, and gastric cancers in five studies; in contrast, one of
the studies reported reduced expression of CHEK1 in brain and CNS cancers. The majority of previous
studies reported that CHEK1 expression is upregulated in various cancers [19,47,51,52], which is in
agreement with this study. Various mechanisms involved in the regulation of CHEK1 expression
and activation were previously described [53–55]. It can also be regulated at the post-transcriptional
level by microRNAs [23,56], which are key regulators of tumor growth and response to treatment [57].
The expression of CHEK1 was further validated, and demonstrated that the CHEK1 gene may possess
either oncogenic or anti-oncogenic characteristics, depending on the type of cancer.
StringAPP plugin Cytoscape prediction indicated that CHEK1 interacts with 10 other proteins,
namely: Ataxia telangiectasia mutated (ATM), cell division cycle 25A and C (CDC25A and
C), exonuclease 1 (EXO1), claspin (CLSPN), RAD51 recombinase (RAD51), ataxia telangiectasia
and Rad3-related protein (ATR), topoisomerase II binding protein 1 (TOPBP1), minichromosome
maintenance complex component 4 (MCM4), and cell division cycle 45 (CDC45). These genes (Figure 6)
were predicted based on co-expression/occurrence, experimental, text-mining, or curated databases.
Further research is recommended to give insight into the relationship of each gene with respect to
CHEK1 in solid tumors.
The CHEK1 gene was altered in 1018 of the queried samples, with a somatic mutation frequency of
1%. As shown in Figure 7, 445 mutations, including 141 duplications, were identified in patients with
multiple samples. The alteration sites were detected within a range of 0 to 300. Out of the alterations,
339 missense mutations, 2 in-frame mutations, and 95 truncating mutations were detected. The CHEK1
mutations primarily occurred in lung cancer, spanning the Pkinase domain, with the hotspots in
T226Nfs*19, T226Hfs*14, and E223G. The hotspot mutations are likely to support tumor development.
The prognosis analysis result showed that reduced CHEK1 mRNA expression is an unfavorable
prognostic factor for patients with gastric and colorectal cancer. Furthermore, the Kaplan–Meier result
was in agreement with the PrognoScan result of lung, ovarian, and breast cancer. The probability of a
reduced survival rate is greater for patients with high CHEK1 gene expression in bladder, brain, lung,
ovary, and breast cancers as compared with patients with low CHEK1 expression. This, therefore,
indicated that comprehensive utilization of bioinformatics analyses is a great approach to study the
prognosis of genes in solid tumors and may be useful to assess the prognosis for several cancer types.
The transition from a normal cell to a cancer cell is caused by four main events, namely proteomic,
transcriptomic, epigenetic, and somatic-acquired genetic alterations [58]. The oncogenic or suppressive
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roles of these alterations occur in specific genomic regions [59]. Using cBioPortal, a significant copy
number alteration in the chosen CHEK1 signature was identified. The analysis queried 10 genes
against the prostate cancer dataset in cBioPortal as shown in Figure 8, and the frequency of alteration
of these genes was 45%. MCM2 had the highest frequency of alteration. Amplification was the main
alteration in all 10 genes, including CHEK1, with 16% of the gene altered through amplification.
Other minor alterations observed include missense mutation, truncating mutation, and deep deletion.
Gene amplification is commonly observed in some solid tumors and has been implicated in tumor
formation [60,61]. Normal cells use the mechanism of gene amplification to overexpress specific genes
for survival under unfavorable conditions, such as during exposure to cytotoxic drugs. This mechanism
is a typical genetic alteration in cancer, and historically, many oncogenes have been identified in the
amplified regions [62]. In light of this, novel cancer-related genes may still be identified in the amplified
regions. Previous studies have shown that CHEK1 is involved in various tumors by influencing the
target genes or signal pathway, which is consistent with this study [12,63–66].
Co-expression analysis revealed that CHEK1 was co-expressed with MCM6 in CRC (Figure 9),
as well as with EXO1 (Figure 6). Previous studies indicated that MCM2 is upregulated in CRC [67],
and the possible association of EXO1 in CRC [68]. The MCMs could potentially be used as a diagnostic
marker. This study, therefore, suggests the significance of the co-expressed genes alongside CHEK1
in CRC.
The quality of the prepared human argonaute protein was confirmed by evaluating the
stereochemical quality of the protein structure with PDBSum (PROCHECK). This suite uses the
Ramachandran plot for structural verification [69]. The output of this analysis proved that the human
argonaute protein was fully prepared, with 89.6% of its amino acid residues located in the right region
(Figure 10A and B). The model protein was used in the molecular docking analysis to study the mode of
regulation of CHEK1 in solid tumors using microRNA. The important amino acids as well as H-bonds
within a specific distance using the human argonaute protein (AGO) and miR-195-5p were investigated.
Argonautes use small RNA guides to recognize target genes. Human argonaute protein (4F3T) was
used for the binding study [70]. MicroRNAs are thought to be crucial in various physiological and
pathological processes, especially in cancer [71–75]. MiR-195-59 has been previously studied in solid
tumors [76–78]. In prostate cancer, miR-195 inhibits tumor progression [79,80]. Other solid tumors in
which this microRNA have been investigated in include CRC [81,82], lung cancer [76,83–85], gastric
cancer [86], cervical cancer [87], breast cancer [88], etc. The common bonds found between proteins
and their corresponding molecules include hydrophobic amino acids and H-bonds.
The docking analysis indicated that the non-covalent interactions between the interacting amino
acid atoms of AGO and specific atoms of miR-195-5p and/or CHEK1 include hydrophobic interactions.
The H-bonds present in the active site of AGO showed that miR-195-5p is essential to CHEK1 regulation
by providing stability and steadiness.
The strong binding affinity of these results was observed through their scores and the amino acid
residues involved in the interaction between CHEK1, miR-195-5p, and AGO. The amino acids (Ala221,
Ile353, Ile365, Ile756, Val797, Val70, Val154, Ile159, Val347, Tyr804, Phe811, Tyr815, and Phe156) and
H-bonds within a distance of 2.0 Å supported that CHEK1 regulation through the human argonaute
protein (4F3T) was driven by miR-195–5p.
4. Materials and Methods
4.1. CHEK1 Expression Analysis (Oncomine Database)
Analysis of CHEK1 transcription levels in various solid tumors was performed by the web-based
cancer microarray database Oncomine at https://www.oncomine.org/resource/login.html. mRNA
expression of clinical tumor and normal samples was compared using a Students’ t-test to generate a
p-value. The threshold search criteria used were a p-value < 1 × 10−8, a fold change > 2, and a gene
rank in the top 1% to obtain the most significant STAT3 probes. A heat map was used to define the
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co-expression profiles of the CHEK1 gene in different types of cancers. The co-expression profiles of
CHEK1 in different cancer types were also extracted from Oncomine and are illustrated as a heat map.
4.2. Identification of CHEK1 Associated Proteins
Search Tool for the Retrieval of Interacting Genes (STRING), accessed at http://string-db.org/,
was used to predict interactive proteins using CHEK1 as a query. STRING (v 11.0) is a unique tool that
provides a comprehensive view of all the known and predicted interactions and associations among
proteins [89]. The output is in the form of a network showing the relationships between genes in the list,
where nodes symbolize genes and links represent networks at a confidence level of 0.90. This network
was visualized with stringAPP, a plugin for Cytoscape v3.7.2 (http://www.cytoscape.org/) [90,91].
4.3. Prognostic Analysis of CHEK1
PrognoScan, accessed at http://dna00.bio.kyutech.ac.jp/PrognoScan/, provides a powerful platform
for evaluating potential tumor markers and therapeutic targets in other to correlate cancer research.
The database also serves as a tool for meta-analysis of the prognostic value of genes [92]. This database
has the ability to evaluate the relationship between gene expression and patient prognosis across a
large collection of cancer microarray datasets. The correlation between CHEK1 expression and survival
was investigated in some selected solid tumors. The significance threshold was adjusted to a Cox
p-value < 0.05.
4.4. Survival Analysis of CHEK1 in Some Selected Solid Tumors
The Kaplan–Meier plotter is a web-based tool accessed at http://kmplot.com/analysis/index.
php?pbackground. The aim of this tool is meta-analysis-based discovery and validation of survival
biomarkers. In this study, the correlations between CHEK1 expression and patient survival in gastric,
breast, lung, and ovarian cancers were analyzed using the Kaplan–Meier plotter. According to various
quantiles of biomarker expression, the tool divides patient samples into pairs of groups to analyze the
prognostic value of a particular gene. The hazard ratio (HR) with 95% confidence intervals (CI) and
log-rank p-value was also computed.
4.5. Complex Genomic Exploration of CHEK1
cBioPortal is an open-access resource for exploring multidimensional genomics data [93].
The database substantially reduces the drawback between complex genomic data and cancer researchers
to provide high-quality access to molecular profiles and their clinical attributes. This further
provides easy result interpretation of rich datasets into biologic insights and clinical application [93].
An integrative analysis of CHEK1 and clinical characteristics was performed using cBioPortal for
Cancer Genomics at http://www.cbioportal.org/index.do, which is a web-based tool for the interactive
visualization and analysis of multidimensional cancer genomics data sets [93,94]. The query interface
combined with personalized data storage enables interactive investigations of genetic alterations
of the CHEK1 gene across available samples. The primary search parameters included alterations
(amplifications, deep deletions, and missense mutations), copy number alterations (CNAs) from GISTIC,
and RNA sequencing data, using the default settings. For the secondary search, RNA sequencing data
were considered.
4.6. Molecular Binding Analysis
The modified method of our previous analysis [56] was employed to investigate the mechanism of
action of CHEK1-miR-195 and human argonaute protein in solid tumors. Schrodinger suit, MiRTarBase,
Discovery Studio Visualizer (v19.1.0.18287), PROCHECK, PATCHDOCK, RNAfold, and RNA-composer
software were all used in this analysis.
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4.7. Statistical Analysis
All statistical analyses (Bar and forest plot) were performed using GraphPad Prism version 6
(GraphPad Software, La Jolla, CA, USA). Survival curves were plotted using the PrognoScan, cBioPortal,
and Kaplan–Meier plotters. All results are displayed with p-values obtained from a long-rank test.
The RMSD was set at 0.030 Å for the protein preparation. The protein quality check at PROCHECK was
also considered significant at 85% and above for residues in the most favored regions. In PatchDock,
RMSD was adjusted to 1.0 Å. Amino acid residues in binding were considered within the distance of
2–3.5 Å, while hydrogen bonding was considered between 2.0 Å. A p-value of < 0.05 were considered
to be statistically significant.
5. Conclusions
Considering the development of cancer through multiple genes’ alteration, an increase in the copy
number of a gene is an effective way to enhance cancer formation. The discovery of cancer-related
genes could provide novel and successful cancer management. CHEK1 is an important irreplaceable
gene. Together with the fatal effects of its deficiency in mammals, it could be used to explain the
paucity of cancer-associated alterations of CHEK1. In this study, the CHEK1 gene was overexpressed in
four different cancers versus normal tissues. Molecular docking based on microRNA gene regulation
may ultimately lead to therapeutic strategies that target CHEK1 in solid tumors. This study suggests
that CHEK1 could be further studied as a promising biomarker for cancer management.
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